RapidAI announced today that it received FDA 510(k) clearance for its Rapid PE Triage & Notification product.
San Mateo, California-based RapidAI designed its Rapid PE Triage & Notification product for the fast identification and communication of suspected central pulmonary embolism (PE).
According to a news release, Rapid PE Triage & Notification works in conjunction with RapidAI’s Rapid Workflow for PE offering. Rapid Workflow for PE, which the company designed to align hospital teams on the treatment of patients suspected of having a pulmonary embolism, was launched in June 2021.
The company said its newly cleared platform will enable care teams to more easily manage the entire patient care journey from the moment a suspected PE patient is identified to diagnosis and through treatment. Patients can be triaged faster and care teams can be aligned more quickly to reduce the overall time to treatment thanks to the automatic identificati…